The N-cadherin inhibitor ADH-1 did not show antitumor potential in a PC3 xenograft tumor model in the research by Li et al. 44 However, ADH-1 could reduce the immunosuppression mediated by IFN-γ according to our data, and the team of Robert Reiter19 reported that N-cadherin-targeted antibodies delayed CRPC progression and growth. The gene discussed is IFNG; the disease is neoplasm.